GFB-887: "Single doses of GFB-887 were well-tolerated with a favorable PK profile in healthy subjects"; Focal segmental glomerulosis (Goldfinch Bio) - Oct 29, 2020 - ASN Kidney Week 2020: "38% GFB-887-treated subjects reported AEs vs. 21% of placebo-treated subjects"
P1 data • Focal Segmental Glomerulosclerosis
|